{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:39:52Z","timestamp":1792391992889,"version":"4.4.0"},"reference-count":47,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":290,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pharmacological and Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Siltartoxatug\u2014developed by Trinomab Pharmaceutical Co., Ltd., using its proprietary HitmAb\u00ae platform\u2014is the first\u2010in\u2010class recombinant monoclonal antibody drug for urgent prophylaxis of tetanus approved by China National Medical Products Administration in February 2025, which addresses the critical unmet need to substitute blood\u2010derived passive immunization preparations for prevention of tetanus. The nonclinical pharmacokinetic and immunogenicity study of siltartoxatug was designed and conducted in strict compliance with global regulatory guidelines for initiating the first\u2010in\u2010human clinical trials. Herein, we report the comprehensive findings from this study. Twenty\u2010four naive cynomolgus monkeys (\n                    <jats:italic>Macaca fascicularis<\/jats:italic>\n                    ) were randomly assigned to four groups each with 6 animals. Monkeys in Group 1 received intravenous infusion of siltartoxatug at 1\u2009mg\/kg. Monkeys in Groups 2, 3, and 4 received intramuscular injection of siltartoxatug at dose of either 1\u2009mg\/kg, 3\u2009mg\/kg, or 10\u2009mg\/kg. Blood samples were collected over 57\u2009days post\u2010administration, and serum drug concentrations and anti\u2010drug antibody levels were determined with validated methods. Results showed that intramuscular administration of siltartoxatug exhibited favorable pharmacokinetic characteristics: primarily systemic distribution with high bioavailability (88.0% at 1\u2009mg\/kg) and low apparent volume of distribution (58.7\u201369.4\u2009mL\/kg), prolonged elimination half\u2010life (11.7\u201312.4\u2009days), short mean time to maximum concentration (1.2\u20132.7\u2009days), and dose\u2010dependent systemic exposure without significant sex differences. Additionally, minimal anti\u2010drug antibody responses were observed. These findings underpinned greater predictability for its clinical translation and informed its first\u2010in\u2010human development.\n                  <\/jats:p>","DOI":"10.1155\/adpp\/2804371","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T05:43:07Z","timestamp":1792388587000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory\u2010Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys"],"prefix":"10.1155","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9569-7173","authenticated-orcid":false,"given":"Xia","family":"Zhou","sequence":"first","affiliation":[{"name":"School of Pharmaceutical Engineering Shenyang Pharmaceutical University  Shenyang 110016 Liaoning China  syphu.edu.cn"},{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7926-7552","authenticated-orcid":false,"given":"Fei","family":"Zhou","sequence":"additional","affiliation":[{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6682-8106","authenticated-orcid":false,"given":"Zhenpeng","family":"Fu","sequence":"additional","affiliation":[{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2702-1708","authenticated-orcid":false,"given":"Weijun","family":"Ye","sequence":"additional","affiliation":[{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2901-9612","authenticated-orcid":false,"given":"Guo","family":"Li","sequence":"additional","affiliation":[{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Li","sequence":"additional","affiliation":[{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0959-3290","authenticated-orcid":false,"given":"Weihong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-1334","authenticated-orcid":false,"given":"Hua-Xin","family":"Liao","sequence":"additional","affiliation":[{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4251-8874","authenticated-orcid":false,"given":"Shaojie","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Engineering Shenyang Pharmaceutical University  Shenyang 110016 Liaoning China  syphu.edu.cn"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3908-5238","authenticated-orcid":false,"given":"Xiaoyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Zhuhai Trinomab Pharmaceutical Co., Ltd.  Zhuhai Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"key":"e_1_2_11_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxicon.2005.02.032"},{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15330"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-4928-9.00034-2"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33131-3"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.02.034"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5297.79"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-019-00096-w"},{"key":"e_1_2_11_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109070"},{"key":"e_1_2_11_9_2","article-title":"Human Tetanus Immunoglobulin, Freeze-Dried","volume":"3","author":"Chinese Pharmacopoeia Commission","year":"2020","journal-title":"Chinese Pharmacopoeia"},{"key":"e_1_2_11_10_2","article-title":"Hypertet\u00ae: Tetanus Immune Globulin (Human) Injection","author":"Grifols Therapeutics LLC","journal-title":"Package insert rev. 8\/2022. U.S. License No. 1871. Research Triangle Park, NC 27709 USA"},{"key":"e_1_2_11_11_2","volume-title":"Guideline on Strategies to Identify and Mitigate Risks for first-in-human and Early Clinical Trials with Investigational Medicinal Products","author":"European Medicines Agency (EMA)","year":"2017"},{"key":"e_1_2_11_12_2","volume-title":"Technical Guideline for Nonclinical Pharmacokinetic Studies of Drugs","author":"Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA)","year":"2020"},{"key":"e_1_2_11_13_2","volume-title":"Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals","author":"ICH S6 (R1)","year":"2011"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2242"},{"key":"e_1_2_11_15_2","volume-title":"Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals","author":"ICH S6","year":"1997"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2018.02.003"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1462429"},{"key":"e_1_2_11_18_2","volume-title":"The Immunological Basis for Immunization Series: Module 3: Tetanus","author":"World Health Organization","year":"2018"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124877"},{"key":"e_1_2_11_20_2","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council","year":"2011"},{"key":"e_1_2_11_21_2","volume-title":"Regulations for the Administration of Affairs Concerning Experimental Animals","author":"The People\u2019s Republic of China, Ministry of Science & Technology","year":"1988"},{"key":"e_1_2_11_22_2","volume-title":"National Medical Products Administration","year":"2017"},{"key":"e_1_2_11_23_2","unstructured":"Organisation for Economic Co-operation and Development OECD Principles of Good Laboratory Practice (ENV\/MC\/CHEM (98)17) 1997."},{"key":"e_1_2_11_24_2","volume-title":"Good Laboratory Practice for Nonclinical Laboratory Studies","author":"U.S. Food and Drug Administration","year":"1979"},{"key":"e_1_2_11_25_2","volume-title":"Guidelines for Validation of Quantitative Analytical Method of Biological Samples","author":"Chinese Pharmacopoeia Commission","year":"2015"},{"key":"e_1_2_11_26_2","volume-title":"Guideline on Bioanalytical Method Validation","author":"EMA","year":"2012"},{"key":"e_1_2_11_27_2","volume-title":"Bioanalytical Method Validation Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"e_1_2_11_28_2","article-title":"Guideline on Immunogenicity Assessment of Therapeutic Proteins","author":"EMA","year":"2017","journal-title":"EMEA\/CHMP\/BMWP\/14327\/2006 Rev 1."},{"key":"e_1_2_11_29_2","volume-title":"Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for in Vivo Clinical","author":"EMA","year":"2012"},{"key":"e_1_2_11_30_2","volume-title":"Guidance for Industry: Immunogenicity Testing of Therapeutic Protein products-developing and Validating Assays for Anti-drug Antibody Detection","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9251-3"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28248038"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.4"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9157-5"},{"key":"e_1_2_11_36_2","article-title":"Drug-Like Properties: Concepts, Structure Design and Method","author":"Di L.","year":"2016","journal-title":"From ADME to Toxicity Optimization[M]"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.28744"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2018.10.003"},{"key":"e_1_2_11_39_2","doi-asserted-by":"crossref","unstructured":"EisenblaetterT.andTeichertL. VogelH. G. MaasJ. andGebauerA. Dose Linearity and Proportionality Drug Discovery and Evaluation: Methods in Clinical Pharmacology. 2011 Springer Berlin Heidelberg https:\/\/doi.org\/10.1007\/978-3-540-89891-7_5.","DOI":"10.1007\/978-3-540-89891-7_5"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2025.2477190"},{"key":"e_1_2_11_41_2","unstructured":"TiwariT. S. P. MoroP. L. andAcostaA. M. Pink Book: Epidemiology and Prevention of Vaccine-Preventable Diseases-Chapter 21-Tetanus. US CDC 2021 https:\/\/www.cdc.gov\/pinkbook\/hcp\/table-of-contents\/chapter-21-tetanus.html."},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajp.20262"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.4.4.5751"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196601272740404"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.298"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0523-5"},{"key":"e_1_2_11_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03791-8"}],"container-title":["Advances in Pharmacological and Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/adpp\/2804371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/adpp\/2804371","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/adpp\/2804371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T05:43:14Z","timestamp":1792388594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/adpp\/2804371"}},"subtitle":[],"editor":[{"given":"Anjali","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1155\/adpp\/2804371"],"URL":"https:\/\/doi.org\/10.1155\/adpp\/2804371","archive":["Portico"],"relation":{},"ISSN":["2633-4682","2633-4690"],"issn-type":[{"value":"2633-4682","type":"print"},{"value":"2633-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2026-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2804371"}}